Objective To determine, from the best available evidence, the effectiveness of surgical pelvic neuroablative techniques as treatment for primary and secondary dysmenorrhoea.
INTRODUCTION
Dysmenorrhoea is the occurrence of painful menstrual cramps of uterine origin. It affects up to 50% of women, 1 with an impact not only on personal health but also an economic impact through loss of working hours 2 along with reduced productivity, diminished work quality and more work-related accidents in those who continue to work. 3, 4 When menstrual pelvic pain is associated with an identifiable pathological condition, such as endometriosis, adenomyosis or pelvic adhesions reflecting previous inflammation, it is considered to be secondary dysmenorrhoea. In contrast, menstrual pain without organic pathology is considered to be primary dysmenorrhoea. 5 The initial onset of primary dysmenorrhoea is usually at or shortly (6±12 months) after menarche, when ovulatory cycles are established. The pain q2000 Blackwell Science Ltd duration is typically 48±72 h and is associated with menstrual flow. In contrast secondary dysmenorrhoea is more likely to occur years after the onset of menarche and occur premenstrually as well as during menstruation.
Overproduction of uterine prostaglandins is probably involved in the aetiology of the typical pain of primary dysmenorrhoea. 6 Prostaglandins are also implicated in secondary dysmenorrhoea; however, anatomical mechanisms can also be identified, depending on the type of accompanying pelvic pathology. 4 Medical therapy includes oral contraceptive pills (OCPs) and nonsteroidal anti-inflammatory drugs (NSAIDs) which both act by suppressing prostaglandin levels. 7 Although the use of both OCPs and NSAIDs has been very successful, there is still a 20±25% failure rate. 8, 9 The ideal neuroablative surgical procedure for pelvic pain would transect all afferent sensory nerves from all the pelvic organs and leave all other nerves unaffected. Whilst pelvic neuroanatomy is complicated and still not completely understood, what is known makes it clear that no such`ideal neuroablative surgical procedure' exists (see Fig. 1 ). The body of the uterus is widely considered to be innervated only by sympathetic nerves. 10 The cervix has predominantly parasympathetic (but also sympathetic) innervation. The afferent sensory nerves from both the uterus and cervix traverse the cervical division of the Lee±Frankenhauser plexus which lies within and around the site of attachment of the uterosacral ligaments to the posterior aspect of the cervix. 11, 12 From the uterosacral ligament, the parasympathetic afferent nerves reach the dorsal root ganglia of the first to fourth sacral spinal nerves (S1± 4) via the pelvic splanchnic nerves (nervi erigentes) and inferior hypogastric nerve plexus (also known as the pelvic plexus) then the superior hypogastric nerve plexus (also known as the`presacral nerve' or hypogastric plexus). 13 The sympathetic afferent nerves emerging from the Lee±Frankenhauser plexus accompany the uterine, iliac and inferior mesenteric arteries to the sacral sympathetic trunk via the sacral splanchnic nerves, some of which bypass the superior hypogastric nerve plexus. Afferent nerves accompany both parasympathetic and sympathetic nerves from the ovary: pain fibres bypass the uterosacral ligament and course through corresponding plexuses to their cells of origin in the dorsal root ganglia of the tenth and eleventh thoracic spinal nerves (T10±11); some of the upper ovarian plexus afferent nerves course directly via renal and aortic plexuses and bypass the superior hypogastric nerve plexus.
Uterine nerve ablation (UNA) involves the transection of the uterosacral ligaments at their insertion into the cervix. Presacral neurectomy (PSN) involves resection of the presacral nerves lying within the boundaries of the interiliac triangle (essentially the superior hypogastric nerve plexus). These procedures both interrupt pelvic afferent sensory nerve fibres and would be expected to diminish uterine pain, 14 although PSN involves the interruption of a greater number of nerve pathways than UNA. Doyle (1955) 15 described a technique of vaginal transection of the uterosacral nerves apparently effective for dysmenorrhoea. Uncontrolled studies have supported the use of laparoscopic uterine nerve ablation (LUNA) for both primary and secondary dysmenorrhoea with either complete relief or substantial reduction in menstrual pain in the majority of subjects.
16±18 Earlier large retrospective studies provide data which have underlined the safety of LUNA. 19 The use of PSN is also supported by uncontrolled studies showing similar results to that of LUNA for both primary and secondary dysmenorrhoea, 20, 21 although PSN probably entails greater operative risk than UNA. 22 However there are limitations to the usefulness of UNA and PSN. A long-term study showed that success rates declined rapidly over time from 72% in the first year to 39% in the fourth for LUNA. 23 Others have suggested a possible risk of anatomical distortion such as uterine prolapse 24, 25 and bladder dysfunction 26 following LUNA. There is also the concern regarding the effects of interruption of the pelvic nerves to the uterine muscles in subsequent pregnancies, such as painless labour. Since both operations interrupt only some of the afferent sensory nerve fibres from the pelvis, neuroablative techniques may be less effective for dysmenorrhoea associated with additional pelvic pathology. For this reason these techniques are often combined with additional treatments such as vaporization of endometrial implants. The objective of this review was to determine the effectiveness of surgical pelvic neuroablative techniques (both laparoscopic and at laparotomy) for the treatment of primary and secondary dysmenorrhoea.
MATERIALS AND METHODS

Search strategy
This review has employed the search strategy developed by the Menstrual Disorders and Subfertility Group. Relevant trials were identified from the Trial Register of the Review Group. The electronic databases Medline (from 1966 to 1998) and Embase (1980±98) were also searched using the following keywords: dysmenorrh$.tw dysmenorrhea/ painful menstruat$.tw pelvic pain/ surgery/ laparoscop$.tw surgical procedures, laparoscopic denervation uterine nerve ablation.tw presacral neurectomy.tw The search was performed on titles, abstracts, and keywords of the listed articles.
In addition citation lists of relevant publications, review articles, and included studies were searched, as were relevant conference abstracts.
Identification of included trials
Inclusion criteria were as follows:
1. randomized controlled trials 2. interventions involving surgical interruption of pelvic nerve pathways (both open and laparoscopic) where it is possible to draw conclusions regarding the effect of the intervention vs. no treatment or vs. another intervention 3. primary outcome of pain relief specified. The other primary outcome was adverse effects. The selection of trials for inclusion in the review was performed independently by two reviewers (M.W. and C.F.) after employing the search strategy described previously. Uncertainties or differences of opinion were resolved by consensus after discussion with the third reviewer (N.J.). The search strategy yielded seven RCTs requiring closer scrutiny. From these, one was excluded 27 which compared laser laparoscopy (involving LUNA and surgical treatment of endometrial implants) with no treatment (diagnostic laparoscopy only) in women with minimal-to-moderate endometriosis. Inclusion criterion 2 above was not fulfilled since there was no control group receiving only laser vaporization so that the effect of the intervention LUNA could not be ascertained. The six included trials were assessed independently by two reviewers for predefined quality criteria and methodological details (displayed in Tables 1, 2 and 3) .
Description and methodological quality of studies
Six trials met the criteria for inclusion in the review. Four trials had been fully published in peer-reviewed journals. 5, 28, 31, 32 Authors from five trials have been contacted to request additional information and/or data. One trial has published only preliminary results and the trial is currently being prepared for full publication with the possibility of further results being available at a later date; 30 further information was supplied in correspondence regarding methodology.
One trial is currently in progress and unpublished data with an interim analysis from this trial were supplied in correspondence. 29 Details of methodology and allocation were supplied for one further trial. 32 Further information has to date not been forthcoming for two trials. 28, 31 A detailed description of the trials assessing women with primary dysmenorrhoea is given in Table 1 , of those assessing UNA in women with endometriosis in Table 2 and those assessing PSN in women with endometriosis in Table 3 . There were no trials assessing pathology causing secondary dysmenorrhoea other than endometriosis.
The surgery involved was performed using standard techniques. LUNA was performed by operative laparoscopy in all four trials describing its use. Lichten & Bombard (1987) 5 described bilateral uterosacral ligament electrocautery at the ligamentous insertion into the cervix until the tissues were blanched (generator power 5.8 watts). The ligaments were then incised using laparoscopic scissors and electrocautery reapplied to the base of the incision. Double blinding was used in two studies; 5,29 one was single-blind; 32 Vercellini et al. 30 used no blinding in follow up, and for the other trial blinding was unclear. 31 It is surprising that few of these trials employed double blinding since this is important when assessing a subjective outcome such as pain relief. However the area which can most seriously jeopardize the reliability of a trial is the randomization process; for only one trial 29 was it clarified that true randomization at the time of surgery, allowing adequate allocation concealment, had taken place. One trial employed the use of case numbers in a process of quasi-randomization, 5 but this trial was otherwise scientifically rigorous and therefore included. A power calculation was performed and adhered to in one study. 31 Tjaden et al. (1990) 32 also included a power calculation but the trial was stopped before the number of patients needed was reached. The monitoring committee surprisingly stopped the trial after evaluation of data from the first 26 patients (only eight of whom had been randomized), as it was considered unethical to deprive patients with midline dysmenorrhoea of the relief afforded by presacral neurectomy.
Data extraction
Linear analogue scales have been validated as the most suitable method of evaluating pain. 35 Some authors using this evaluation method have chosen to dichotomize the data obtained; there is evidence to suggest that dichotomous outcomes can be derived from continuous data when interpreting pain relief data. 36 The outcome`pain relief' may be reported as dichotomous (pain relief or not) or continuous data. Table 4 ). 
RESULTS
Primary dysmenorrhoea
The intervention LUNA (see Table 4 ) effected a significant difference in pain relief for up to 6 months of follow-up (odds ratio, OR 15.5); both LUNA and control groups were comparable prior to the intervention. Pain relief assessed at 12 months also showed a significant difference between the groups (OR 10.9).
For LUNA vs. LPSN (see Table 4 ) there was no significant difference in pain relief between the two treatments up to 6 months of follow-up (OR 0.7). However at more than 6 months' follow up, the LPSN group had significantly better pain relief scores (OR 0.1). There was a highly significant difference in the number of adverse effects reported by the participants: 94% of the PSN group reported constipation with no complications being reported in the LUNA group (OR 0.02).
Secondary dysmenorrhoea
For UNA with surgical treatment of endometriosis vs. surgical treatment of endometriosis alone, both trials found no significant difference in pain relief. Dover et al. (1999) 29 reported comparable baseline pain scores, and at 6 months postoperatively found no significant difference between the experimental and group. An intention-to-treat analysis on subject satisfaction showed that 68% of the experimental group and 73% of the control group were very satisfied or satisfied with treatment, while 32% of the experimental group and 27% of the control group were uncertain, dissatisfied, or very dissatisfied with treatment. No adverse effects were reported for either group. For PSN with surgical treatment of endometriosis vs. surgical treatment of endometriosis alone, Candiani et al. (1992) 31 found no significant difference between the experimental and control groups overall (OR 1.6) (see Table 4 ). However the authors originally collected information on the incidence, site and severity of pain and in analysis split their results into separate areas of pain. They interpreted their findings as showing a marked reduction in the recurrence of midline abdominal dysmenorrhoeic pain; however, this was at the borderline of statistical significance (P 0.06). There was a highly significant difference in the proportion of patients with adverse effects from the treatment: the control group reported none but in the PSN group 13 women reported constipation, three urinary urgency, and two experienced a painless first stage of labour (OR 14.6). Tjaden et al. (1990) 32 also originally collected information on incidence and location of pain and classified pain relief into areas. They found that the experimental and control groups were significantly different in pain relief for midline abdominal pain (Fisher exact test, P 0.03). However for back pain or lateral pain associated with dysmenorrhoea there were no significant differences between the groups. These results are based on only the eight randomized participants. One woman experienced transient urinary urge incontinence for 2 weeks following PSN; no complications occurred in the group who did not undergo PSN.
DISCUSSION
This systematic review has drawn on the results of six RCTs examining surgical pelvic neuroablation for chronic pelvic pain. Data were analysed from a total of 295 women who were randomly allocated treatment in these trials. Of these, 115 women underwent LUNA (46 with primary dysmenorrhoea, 69 with endometriosis), 33 underwent LPSN (all of whom had primary dysmenorrhoea) and 39 underwent PSN at laparotomy (all of whom had endometriosis). Laparoscopic and open techniques could be combined for these interventions, as there is evidence to suggest they have similar ranges of pain relief for dysmenorrhoea. 18, 20 LUNA is effective for pain relief in primary dysmenorrhoea in the short term but its effectiveness may decline over time. 5 Chen et al. (1996) 28 confirm this suggestion and demonstrate that LPSN may retain its effectiveness for longer. The importance of longterm follow up for future trials must be emphasised. Neuroablative procedures appear less effective when used as an adjunct to standard conservative surgery for endometriosis. However PSN may be effective for midline pain associated with endometriosis, but not for other types of pain such as non-menstrual pain, lateral pain and deep dyspareunia, and so is unlikely to modify substantially the subjective and social impact of the condition. Careful study of Fig. 1 clarifies why PSN might be more effective than LUNA, since transection of the superior hypogastric nerve plexus would ablate a higher proportion of relevant afferent nerves than transection of the Lee±Frankenhauser nerve plexus. It also explains why UNA could be particularly ineffective for pain arising from the ovary or adjacent tissues, as could be the case in ovarian or paraovarian endometriosis, since all ovarian afferent nerves bypass the Lee± Frankenhauser plexus and many of the pain fibres bypass both of these nerve plexuses. Unless a periarterial sympathectomy of the iliac, inferior mesenteric and ovarian vessels is performed, a number of afferent fibres will always be left intact. More convincing is the high incidence of adverse effects following PSN. Complications were reported in women who underwent PSN in all trials. Out of 33 women who underwent LPSN, 31 experienced constipation, which was very severe in some cases. No complications were reported in women randomly allocated to LUNA! LPSN is a surgical procedure which requires a high degree of skill from an experienced pelvic laparoscopic surgeon trained specifically in this retroperitoneal operation. The presacral region may be highly vascular and the procedure carries major potential hazards for the unwary or inadequately trained surgeon. The Royal College of Obstetricians and Gynaecologists classifies LPSN as a level 4 procedure, requiring advanced skills. Conversely, although LUNA must be performed precisely to avoid complications, it should be within the scope of all competent pelvic laparoscopic surgeons.
There is definitely a place for further well-designed RCTs examining the intervention of LUNA, which could be realistically available to all women. The high degree of specialized skill required to perform LPSN and the high likelihood of complications from PSN (whether performed laparoscopically or at laparotomy) bring into question whether further work is required. The view of the authors is that clinicians should consider the situation very carefully before performing this operation, even in the context of a RCT. This review suggests that women with endometriosis are a different population from women with primary dysmenorrhoea when pain relief from LUNA is considered. Ideally these populations should be studied separately. For primary dysmenorrhoea, in order to have 80% power at 95% confidence level to detect benefit in 50% of women, assuming`benefit' in 10% controls, at least 48 participants would be required for analysis following randomization. For endometriosis, in order to have 80% power at 95% confidence level to detect benefit in 90%, assuming benefit in 60% controls undergoing conventional endometriosis surgery, 27 at least 76 participants would be required for analysis following randomization.
The authors are aware of two further ongoing trials: 1. A multicentre RCT to assess the efficacy of laparoscopic uterosacral nerve ablation (LUNA) in the treatment of chronic pelvic pain (University of Birmingham Clinical Trials Unit, UK). The trialists aim to randomly allocate 120 women with minimal endometriosis, minor adhesions or no visible pelvic pathology on laparoscopy.
2. LUNA for chronic pelvic pain: an RCT at the University Department of Obstetrics and Gynaecology, National Women's Hospital, Auckland, New Zealand. The trialists aim to randomly allocate 50 women with primary dysmenorrhoea and 80 women with endometriosis.
CONCLUSION
There is insufficient evidence to recommend the use of surgical pelvic neuroablation in the management of dysmenorrhoea, regardless of cause. Further scientifically rigorous RCTs should be undertaken and the results of the above trials are eagerly anticipated.
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